Guillain-Barre syndrome after COVID-19 in Japan

被引：20

作者：

Hirayama, Takehisa ^{[1
]}

Hongo, Yu ^{[2
]}

Kaida, Kenichi ^{[3
]}

Kano, Osamu ^{[1
]}

机构：

[1] Toho Univ, Omori Med Ctr, Dept Neurol, Ota Ku, Tokyo, Japan

[2] Natl Def Med Coll, Div Neurol Antiaging & Vasc Med, Dept Internal Med, Tokorozawa, Saitama, Japan

[3] Saitama Med Ctr, Dept Neurol, Kawagoe, Saitama, Japan

来源：

BMJ CASE REPORTS | 2020年 / 13卷 / 10期

关键词：

peripheral nerve disease; TB and other respiratory infections; immunology;

D O I：

10.1136/bcr-2020-239218

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

We report the first case of Guillain-Barre syndrome (GBS) associated with SARS-CoV-2 infection in Japan. A 54-year-old woman developed neurological symptoms after SARS-CoV-2 infection. We tested for various antiganglioside antibodies, that had not been investigated in previous cases. The patient was diagnosed with GBS based on neurological and electrophysiological findings; no antiganglioside antibodies were detected. In previous reports, most patients with SARS-CoV-2-infection-related GBS had lower limb predominant symptoms, and antiganglioside antibody tests were negative. Our findings support the notion that non-immune abnormalities such as hyperinflammation following cytokine storms and microvascular disorders due to vascular endothelial damage may lead to neurological symptoms in patients with SARS-CoV-2 infection. Our case further highlights the need for careful diagnosis in suspected cases of GBS associated with SARS-CoV-2 infection.

引用

页数：4

共 23 条

[21]

Uncini A., 2020, J NEUROL NEUROSURG P, V0, P1

[22] Neurological Manifestations of COVID-19: A systematic review and current update [J].

Whittaker, Abigail ;

Anson, Matthew ;

Harky, Amer .

ACTA NEUROLOGICA SCANDINAVICA, 2020, 142 (01) :14-22

[23] Peripheral neuropathies and anti-glycolipid antibodies [J].

Willison, HJ ;

Yuki, N .

BRAIN, 2002, 125 :2591-2625

← 1 2 3 →